Medicine Stock Disruptions Hit South Africa, Leaving Patients Scrambling

"Medicines most frequently affected by stock disruptions included certain antibiotics, tuberculosis medicines, oncology products, insulin, and selected paediatric antiretroviral medicines," Motsoaledi said.

Medicine stock disruptions are a growing concern in South Africa, with Health Minister Dr. Aaron Motsoaledi revealing that critical medications including antibiotics, TB treatments, and cancer medications are frequently affected by stock disruptions.

As the country's public health system grapples with the challenge, Motsoaledi listed the provinces most affected by stock disruptions as the Eastern Cape, Mpumalanga, and North West provinces. "Based on information obtained from the NSC, provinces most affected by stock disruptions were the Eastern Cape, Mpumalanga, and North West provinces," Motsoaledi said.

The Health Department has been managing and monitoring medicine availability through routine reporting systems, including RxSolution and the Stock Visibility System (SVS), which submit weekly data to the National Surveillance Centre (NSC).

Routine biannual stocktaking at provincial depots, targeted assessments, and stock visibility reporting at depots, hospitals, and clinics are also undertaken to identify, monitor, and address medicine supply disruptions.

"Oncology medicine supply remains challenging due to reliance on a limited number of international manufacturers," Motsoaledi said.

To address the issue, the department has implemented various interventions including routine reporting systems, biannual stocktaking, and targeted assessments.

The Health Minister has also stated that the department has not conducted a national audit of medicine stock at all public hospitals and clinics in the past 12 months.

The lack of a national audit raises concerns about the adequacy of the Health Department's efforts to address medicine stock disruptions. The reliance on international manufacturers for oncology medicines also raises concerns about supply chain vulnerabilities.

The situation is concerning, especially given the critical role that these medications play in treating life-threatening illnesses such as tuberculosis and cancer.

The Health Department must take concrete steps to address the challenges affecting medicine availability and ensure that all provinces have adequate stock levels of essential medications.